Business Wire

RAM Active Investments Launches the RAM Diversified Alpha Fund (UCITS)

Share

RAM Active Investments SA ("RAM AI"), a systematic asset manager based in Geneva, is launching the RAM (LUX) SYSTEMATIC FUNDS – DIVERSIFIED ALPHA (the “Fund”), a fund which will seek to deploy a robust and stable systematic investment process to exploit volatility and dispersion within a broadly diversified global asset allocation, with the intention of offering asymmetric returns that have low correlation to global markets.

“Technological innovation is a key component of the portfolio construction methodology”, explains Maxime Botti, Founding Partner & Senior Fund Manager at RAM AI who heads the systematic macro team formed by Philippe Huber and Tony Guida, Fund Managers and Researchers. “We used a similar methodology than our Alternative Investment Fund strategy which has the objective to provide uncorrelated returns to mainstream asset classes over the medium-term”.

The Fund aims at acting as a real diversifier in a global asset allocation by seeking to deliver absolute returns, not only during normal market conditions but also when it is the most needed during market jolt periods.

The approach to dispersion modelling is agnostic and adaptive. RAM AI models the relationships between liquid assets by analysing them on a relative basis and through multiple dimensions. RAM AI’s expansive and evolving computational capabilities allow to analyse on an ongoing basis a large amount of data to identify the most profitable strategies across time frames spanning from short to long-term.

“Relying on techniques borrowed from natural sciences for solving multi-dimensional problems, the use of genetic algorithm that replicates evolution allows our models to select the fittest alphas, making the overall strategy more robust” adds Philippe Huber.

As financial markets change (less independent, central banks interventions, etc.), so does our model” shares Tony Guida. The Fund benefits from a robust process of alpha creation and selection; alphas are reassessed several times per year to take into account evolving market conditions.

The Fund is available in a UCITS format as of the 10th of November 2020 to investors in France, Finland, Germany, Italy, Luxembourg, Norway, Portugal, Sweden, Switzerland and United Kingdom.

RAM Active Investments

RAM Active Investments is a systematic asset manager with a long experience in creating value for its customers in any market condition. Research is at the heart of our disciplined approach to investment, which enables us to identify and continually exploit new market inefficiencies by adopting the latest innovative technologies.

Founded in 2007 by Thomas de Saint-Seine, Maxime Botti and Emmanuel Hauptmann, RAM Active Investments, an affiliate of Mediobanca Group since March 2018, operates independently worldwide with more than 40 employees and four offices in Geneva (headquarter), Zurich, Luxembourg and Milan. Asset under Management of USD 2 billion as of end of June 2020.

To find out more about RAM Active Investments visit the website ram-ai.com or follow us on LinkedIn.

About the team

Philippe Huber joined RAM AI in 2017 as a Senior Quantitative Analyst to work on the development of systematic investment strategies. In 2020, he became Fund Manager of the RAM Diversified Alpha and continues his focus on the development of a proprietary suite of back testing and non-traditional optimisation tools in Cuda/C++ to run on GPUs.

Philippe is an award-winning PhD in Econometrics and Statistics (University of Geneva, 2004), a graduate of the EPFL (MSc, Physics, 1998) and a graduate of the University of Geneva (MSc, Econometrics and Statistics, 2001).

Tony Guida joined RAM AI in 2019 as a Senior Quantitative Researcher and became Fund Manager of the Diversified Alpha in 2020. His work focuses primarily on extracting market inefficiencies from different sources from traditional fundamentals, market signals, alternative data, and machine learning. His expertise is in mid to low frequency in equities.

Tony started his career at Unigestion in the quantitative equity low volatility team and later became a member of the research and investment committee for Minimum Variance Strategies, where he led the factor investing research group for institutional clients. In 2015, he moved to Edhec Risk Scientific Beta as a Senior Consultant for Risk allocation and factor strategies before going to a major UK pension fund in 2016 to build the in-house systematic equity, co-managing 6 billion GBP as a senior quantitative portfolio manager.

Philippe and Tony have a number of publications under their names in some of the best academic research journals, including the recently published “Genetic Algorithms: A heuristic approach to multi-dimensional problems”.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lidia Marqués
Head of Communications & Events
Email: ram-communication@ram-ai.com
Phone: +41 58 726 87 27

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye